Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;18(11):1500-1502.
doi: 10.2215/CJN.0000000000000221. Epub 2023 Jun 14.

Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation

Hiddo J L Heerspink  1 , Stefan Berger  2 , Ron T Gansevoort  2 ; Renal Life Cycle Trial Investigators
Collaborators, Affiliations

Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation

Hiddo J L Heerspink et al. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

S. Berger reports consultancy for Chiesi and Novartis; research funding from Chiesi and Novartis; honoraria from Astellas and Novartis; and advisory or leadership roles for Advisory Board for Novartis and Supervisory Board for Dutch Transplant Foundation. R.T. Gansevoort reports consultancy for AstraZeneca, Bayer, Galapagos, Mironid, and Sanofi-Genzyme; research funding from Abbvie, AstraZeneca, Bayer, Galapagos, Otsuka Pharmaceuticals, Roche, and Sanofi-Genzyme; role on the Editorial Boards of American Journal of Kidney Diseases, CJASN, Journal of Nephrology, Kidney360, and Nephron Clinical Practice; and role as Editor of Nephrology Dialysis Transplantation and member of the Council of the European Renal Association. H.J.L. Heerspink reports ongoing consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, Janssen, Merck, Novartis, Novo Nordisk, and Travere Pharmaceuticals; research funding from AstraZeneca, Boehringer Ingelheim, Janssen research support (grant funding directed to employer), and Novo Nordisk; lecture fees from AstraZeneca and Novo Nordisk; and speakers bureau for AstraZeneca.

Figures

Figure 1
Figure 1
Potential cardiorenal protective mechanisms for SGLT inhibition mediated via tubular SGLT2 and via mechanisms working direct on the heart and the kidney. NHE-1, sodium–hydrogen exchange 1; SGLT2, sodium‐glucose cotransporter‐2. Adapted from Udell JA, Jones WS, Petrie MC, et al. Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week. J Am Coll Cardiol. 2022;79(20): 2058–2068.
See this image and copyright information in PMC

References

    1. Heerspink HJL Stefánsson BV Correa-Rotter R, et al. . Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/nejmoa2024816 - DOI - PubMed
    1. Herrington WG Staplin N Wanner C, et al. .; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. doi:10.1056/nejmoa2204233 - DOI - PMC - PubMed
    1. Rossing P Caramori ML Chan JCN, et al. . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1–S127. doi:10.1016/j.kint.2022.06.008 - DOI - PubMed
    1. UK Kidney Association Clinical Practice Guideline Working Group. Sodium-Glucose Co-transpOrter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. Accessed February 2, 2023. https://ukkidney.org/sites/renal.org/files. - PMC - PubMed
    1. Juni RP Al-Shama R Kuster DWD, et al. . Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. Kidney Int. 2021;99(5):1088–1101. doi:10.1016/j.kint.2020.12.013 - DOI - PubMed

Publication types

MeSH terms

Substances